French recommendations have been published on physical activity and nutrition for patients with digestive cancer. The FOLFOX6m regimen is more convenient and cost-effective than FOLFOX4 for non-metastatic colon cancer treatment, with equivalent or better tolerance and higher 5-FU intensity. Studies have shown equivalent outcomes with FOLFOX6m compared to FOLFOX4 in adjuvant treatment for stage III colon cancer.